NCT00077974View on ClinicalTrials.gov

A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

SU011248

50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity

Trial Locations (15)

10021

Pfizer Investigational Site, New York

10022

Pfizer Investigational Site, New York

19111

Pfizer Investigational Site, Philadelphia

27705

Pfizer Investigational Site, Durham

44195

Pfizer Investigational Site, Cleveland

48109

Pfizer Investigational Site, Ann Arbor

53792

Pfizer Investigational Site, Madison

55905

Pfizer Investigational Site, Rochester

91105

Pfizer Investigational Site, Pasadena

94115

Pfizer Investigational Site, San Francisco

97213

Pfizer Investigational Site, Portland

91010-3000

Pfizer Investigational Site, Duarte

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

02215

Pfizer Investigational Site, Boston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY